Vanguard Group Inc. Acquires 296,181 Shares of Novavax, Inc. (NASDAQ:NVAX)

Vanguard Group Inc. grew its position in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 1.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,726,250 shares of the biopharmaceutical company's stock after buying an additional 296,181 shares during the quarter. Vanguard Group Inc. owned 9.82% of Novavax worth $126,439,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in NVAX. Spire Wealth Management bought a new position in Novavax in the fourth quarter valued at approximately $29,000. KBC Group NV increased its stake in shares of Novavax by 97.0% in the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 3,917 shares during the last quarter. TigerOak Management L.L.C. acquired a new position in shares of Novavax during the 4th quarter worth $86,000. AlphaQuest LLC lifted its position in shares of Novavax by 290.1% during the 4th quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 7,940 shares during the last quarter. Finally, Xponance Inc. acquired a new stake in Novavax in the fourth quarter valued at about $95,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Trading Up 7.9 %

NVAX traded up $0.43 during trading on Friday, reaching $5.86. 6,647,848 shares of the company's stock were exchanged, compared to its average volume of 8,225,699. The stock has a market capitalization of $942.55 million, a PE ratio of -2.59, a price-to-earnings-growth ratio of 2.85 and a beta of 3.15. Novavax, Inc. has a one year low of $3.81 and a one year high of $23.86. The firm has a fifty day moving average price of $7.48 and a two-hundred day moving average price of $8.80.

Remove Ads

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million for the quarter, compared to the consensus estimate of $85.48 million. During the same quarter last year, the business earned ($1.44) earnings per share. Sell-side analysts expect that Novavax, Inc. will post -1.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on NVAX. TD Cowen raised shares of Novavax to a "hold" rating in a report on Thursday, February 27th. BTIG Research initiated coverage on shares of Novavax in a research report on Friday, February 28th. They issued a "buy" rating and a $19.00 target price on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $18.00.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.